Skip to main content
Fig. 6 | Cellular & Molecular Biology Letters

Fig. 6

From: MicroRNA-146a protects against myocardial ischaemia reperfusion injury by targeting Med1

Fig. 6

MicroRNA-146a decreased the apoptosis of H9C2 in stimulation of hypoxia and re-oxygenation by targeting Med1. a MicroRNA-146a inhibitor suppressed the expression of microRNA 146a in H9C2 cells. Compared with negative control group, *P < 0.05, n = 6. b MicroRNA-146a inhibitor increased the expression of TRAP220 encoded by Med1 gene, *P < 0.05, n = 6. c Med1-RNAi downregulated the expression of TRAP220 in H9C2 cells which was upregulated by microRNA-146a inhibitor. Compared with control group, #P < 0.05, n = 6; Compared with Inhibitor group, *P < 0.05, n = 6. d MicroRNA-146a inhibitor increased the apoptosis of H9C2 after hypoxia and re-oxygenation, which was decreased by Med1-RNAi. d-(a). CON group: H9C2 cells; d-(b). IR group: H9C2 cells experienced hypoxia and re-oxygenation; d-(c). Inhibitor-NC + IR group: H9C2 cells were stimulated with microRNA-146a inhibitor negative control and then experienced hypoxia and re-oxygenation; d-(d). Inhibitor + IR group: H9C2 cells were stimulated with microRNA-146a inhibitor and then experienced hypoxia and re-oxygenation; d-(e). Inhibitor + Med1-RNAi-NC + IR group: H9C2 cells were treated with microRNA-146a inhibitor and then transfected with Med1-RNAi-negative control. Then, these H9C2 cells were stimulated with hypoxia and re-oxygenation; d-(f). Inhibitor + Med1-RNAi + IR group: H9C2 cells were treated with microRNA-146a inhibitor and then transfected with Med1-RNAi. Then, these H9C2 cells were stimulated with hypoxia and re-oxygenation. d-(g). ANOVA was performed for between-group comparisons in the experiment. Compared with CON group, *P < 0.05, n = 6; compared with Inhibitor-NC + IR group, #P < 0.05, n = 6; compared with Inhibitor + Med1-RNAi-NC + IR group, &P < 0.05, n = 6. CON: control group; NC: negative control; Inhibitor: microRNA-146a inhibitor; Med1-RNAi: Lenti-Med1 shRNA; Med1-RNAi-NC: Lenti-Med1 shRNA negative control

Back to article page